¼¼°èÀÇ ¼³Æù¾Æ¹Ìµå ½ÃÀå : Åõ¿© °æ·Îº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¿¹Ãø(2024-2032³â)
Sulphonamides Market, By Route of Administration, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1514975
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 263 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,526,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,476,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,869,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¼³Æù¾Æ¹Ìµå ½ÃÀå ±Ô¸ð´Â 2023³â 1¾ï 2,940¸¸ ´Þ·¯·Î 2024-2032³â¿¡ °ÉÃÄ CAGR 4.50%·Î È®´ë

¼³Æù¾Æ¹Ìµå ½ÃÀå - ½ÃÀå ¿ªÇÐ

Àü¿°º´, ¸¸¼º Áúȯ Áõ°¡, º´¿ë ¿ä¹ý¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹Ãø

Àü¿°º´ÀÌ °è¼ÓÇØ¼­ ¼¼°èÀÇ °Ç°­»óÀÇ Å« °úÁ¦°¡ µÇ°í Àֱ⠶§¹®¿¡ ¼³Æù¾Æ¹Ìµå¿Í °°Àº È¿°úÀûÀÎ Ç×»ýÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ´ëÆø Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿ä·Î °¨¿°, È£Èí±â °¨¿°, ¼º °¨¿°°ú °°Àº ¼¼±Õ °¨¿° Áõ°¡´Â ¼³Æù¾Æ¹Ìµå ½Ã½ºÅÛÀ» Æ÷ÇÔÇÑ Ç×»ýÁ¦ÀÇ Çʿ伺À» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¼³Æù¾Æ¹Ìµå´Â ·ù¸¶Æ¼½º °üÀý¿°(¼úÆÄ»ì¶óÁø µî) ¹× ¿°Áõ¼º Àå Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ Ä¡·á¿¡µµ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ÀÇ È®»êÀº ¼³Æù¾Æ¹Ìµå ¼ººÐÀ» Æ÷ÇÔÇÑ ÀǾàǰ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿äÀÇ ¿øµ¿·ÂÀÌ µÇ¾ú½À´Ï´Ù.

¼³Æù¾Æ¹Ìµå´Â Á¾Á¾ Æ®¸®¸ÞÅäÇÁ¸² ¹× ÄÚÆ®¸®¸ñ»çÁ¹°ú °°Àº ´Ù¸¥ Ç×»ýÁ¦¿Í ÇÔ²² »ç¿ëµÇ¾î È¿´ÉÀ» ³ôÀÌ°í ³»¼º ¹ÚÅ׸®¾Æ¿¡ ´ëÇ×ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º´¿ë ¿ä¹ýÀÇ °³¹ß°ú »ç¿ëÀº ÀÓ»ó ÇöÀå¿¡¼­ ¼³Æù¾Æ¹Ìµå ¼ö¿ä¿¡ ±â¿©ÇÕ´Ï´Ù. ¼³Æù¾Æ¹Ìµå´Â »õ·Î¿î Ç×»ýÁ¦¿¡ ºñÇØ ´õ Àú·ÅÇÕ´Ï´Ù. ÀÌ ºñ¿ë È¿°ú´Â Á¦ÇÑµÈ ÀÚ¿øÀ» °¡Áø ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ƯÈ÷ Áß¿äÇϸç, ÀÌ·¯ÇÑ Ç×»ýÁ¦¿¡¼­µµ È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¼³Æù¾Æ¹Ìµå ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 4.50%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.

Åõ¿© °æ·Îº°·Î, °æ±¸ ¾à¹° ºÎ¹®Àº ÃÖ±Ù COVID-19ÀÇ À§±â¿Í Ä¡·á¿¡ ÀÇÇØ 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ëµµº° ºÎ¹®¿¡¼­ ¿ä·Î °¨¿°(UTI) ºÎ¹®Àº 2023³â ÁÖ¿ä ¿ëµµ¿´½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î ºñ´¢±â, ´ç´¢º´ ¹× ±âŸ ¸¸¼º ÁúȯÀÇ Ä¡·á¿¡ ´ëÇÑ ³ôÀº ¿ä±¸·Î ÀÎÇØ º´¿ø ºÎ¹®Àº 2023³â ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ¿´½À´Ï´Ù.

Áö¿ªº°·Î´Â ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ ºÏ¹Ì°¡ 2023³â ¸ÅÃâÀ» À̲ø°í ÀÖ½À´Ï´Ù.

¼³Æù¾Æ¹Ìµå ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼³Æù¾Æ¹Ìµå ¼¼°è ½ÃÀåÀº Åõ¿© °æ·Î, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ±¸ºÐµË´Ï´Ù.

½ÃÀåÀº Åõ¿©°æ·Î¿¡ µû¶ó °æ±¸Á¦, ¿Ü¿ëÁ¦, ±âŸ 3°¡Áö·Î ºÐ·ùµË´Ï´Ù. ½ÃÀåÀ» µ¶Á¡ÇÏ´Â °ÍÀº °æ±¸Á¦ÀÔ´Ï´Ù. Ç×»ýÁ¦¿Í °¨¿° Ä¡·á¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä°¡ ½ÃÀå ¼ºÀåÀ» º¸¿ÏÇϰí ÀÖ½À´Ï´Ù.

¿ëµµº°·Î´Â ÇǺΠ°¨¿°, ¿ä·Î °¨¿°(UTI), È£Èí±â °¨¿°(RTI), À§Àå°ü °¨¿°(GIT) µî 5°¡Áö·Î ºÐ·ùµË´Ï´Ù. PCR ¹æ¹ý ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ºñ´¢±â °ü·Ã Áúº´ Áõ°¡¿Í ¿ä·Î °á¼®¿¡ ´ëÇÑ »õ·Î¿î ¿¬±¸°¡ÀÌ ºÎ¹® ¼ö¿ä¿¡ ±â¿©ÇÕ´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î º´¿ø, Ŭ¸®´Ð ¹× ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÎ¹®Àº ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±â¼úÀÇ Áøº¸¿Í ÇǺÎ, ½ÅÀå °¨¿°ÀÇ Ä¡·á°¡ ÁÖ·Î ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¼³Æù¾Æ¹Ìµå ½ÃÀå - Áö¸®Àû ÅëÂû

¼³Æù¾Æ¹Ìµå ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì, ¼­À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç(ÀϺ», È£ÁÖ µî)Àº ÀÇ·á ½Ã½ºÅÛÀÌ È®°íÇÑ ¼±Áø Áö¿ªÀÌ¸ç ¼³Æù¾Æ¹ÌµåÀÇ ¼Òºñ·®ÀÌ ¸¹½À´Ï´Ù. ÀÌ´Â ÀÇ·á ½Ã¼³¿¡ ´ëÇÑ Á¢±ÙÀÌ ÁÁ±â ¶§¹®ÀÔ´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«, µ¿À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç(Àεµ, Áß±¹ µî), ¾ÆÇÁ¸®Ä« ±¹°¡¿¡¼­´Â ÀÇ·áºñ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶ó °³¼±ÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

¼³Æù¾Æ¹Ìµå ½ÃÀå - °æÀï ±¸µµ:

¼³Æù¾Æ¹Ìµå ½ÃÀåÀÇ °æÀïÀº Àû´çÇÕ´Ï´Ù. °¢ ȸ»ç´Â °¢ Áö¿ª ½ÃÀå ȯ°æ, ±ÔÁ¦ ȯ°æ, ÀÇ·á Á¦µµ¿¡ ¸ÂÃß¾î Àü·«À» ¼¼¿ì°í ÀÖ½À´Ï´Ù. ÀüÅë ±â¾÷Àº Á¾Á¾ ¿©·¯ ³ª¶ó¿¡ °ÉÃÄ ÆÇ¸Å ³×Æ®¿öÅ©¸¦ °¡Áø ¼¼°èÀÇ Á¸Àç°¨À» º¸¿©ÁÝ´Ï´Ù. Á¦Á¶ °øÁ¤°ú ±â¼úÀÇ ¹ßÀüÀº °æÀïÀû À§Ä¡¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¦Á¶ ¹× Á¦Çü °­È­¸¦ À§ÇØ ½Å±â¼úÀ» äÅÃÇϰí ÅëÇÕÇÏ´Â ±â¾÷Àº È¿À²¼º°ú Á¦Ç° ǰÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼³Æù¾Æ¹Ìµå ÀǾàǰÀÇ »õ·Î¿î Á¦ÇüÀ» °³¹ßÇϰí, È¿´ÉÀ» Çâ»ó½Ã۰í, ºÎÀÛ¿ëÀ» ¿ÏÈ­Çϱâ À§ÇØ °æÀï»ç´Â ¿¬±¸ °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸°¡ ½ÃÀå¿¡¼­ÀÇ Çõ½Å°ú Â÷º°È­ÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼³Æù¾Æ¹ÌµåÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¼³Æù¾Æ¹Ìµå »ê¾÷ ¿¬±¸

Á¦5Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå »óȲ

Á¦7Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå-Åõ¿© °æ·Îº°

Á¦8Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå-¿ëµµº°

Á¦9Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå - ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå ¼³Æù¾Æ¹Ìµå ½ÃÀå-Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼®-¼³Æù¾Æ¹Ìµå ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Sulphonamides Market size was valued at USD 129.40 Million in 2023, expanding at a CAGR of 4.50% from 2024 to 2032.

Sulphonamides, also known as sulfonamides, are a class of synthetic antimicrobial agents that work by inhibiting bacterial growth. Sulphonamides is used to treat a range of infections, including urinary tract infections, respiratory tract infections, bacterial meningitis, and some sexually transmitted infections. They are also sometimes used in combination with other antibiotics for synergistic effects.

Sulphonamides Market- Market Dynamics

Growing prevalence of infection, chronic diseases and high demand for combinational therapies are expected to propel market demand

As infectious diseases continue to pose significant global health challenges, the demand for effective antibiotics like sulphonamides is rising significantly. The rise in bacterial infections such as urinary tract infections, respiratory infections, and sexually transmitted diseases drives the need for antibiotics, including sulphonamides. Sulphonamides are also used in the treatment of chronic conditions such as rheumatoid arthritis (e.g., sulfasalazine) and inflammatory bowel disease. The prevalence of these conditions drives ongoing demand for medications containing sulphonamide components.

Sulphonamides are often used in combination with other antibiotics like trimethoprim e.g., co-trimoxazole to enhance efficacy and combat resistance. The development and use of such combination therapies contribute to the demand for sulphonamides in clinical practice. Sulphonamides are more affordable compared to newer antibiotics. This cost-effectiveness is particularly important in healthcare systems with limited resources, where these antibiotics can still provide effective treatment options. These factors are expected to bolster market growth.

Sulphonamides Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.50% over the forecast period (2024-2032)

Based on Route of Administration segmentation, the oral segment was predicted to show maximum market share in the year 2023, owing to the recent COVID-19 crisis & cure.

Based on Application segmentation, the urinary tract infection (UTI) segment was the leading Application in 2023, owing to rising bacterial infection that causes mortality also.

Based on End User segmentation, the hospital segment was the leading End User in 2023, owing to the high need for treatment of urinary, diabetic, and other chronic disorders.

On the basis of region, North America was the leading revenue generator in 2023, owing to high prevalence of chronic diseases.

Sulphonamides Market- Segmentation Analysis:

The Global Sulphonamides Market is segmented on the basis of Route of Administration, Application, End User, and Region.

The market is divided into three categories based on the Route of Administration: oral, topical, and others. The oral segment dominates the market. The high demand for antibiotics and infectious disease treatment is supplementing the market growth.

The market is divided into five categories based on the Application: skin infection, urinary tract infection (UTI), respiratory tract infection (RTI), gastrointestinal tract (GIT), and others. The PCR-based method segment dominates the market. Rising urinary-related diseases and new research in UTIs is contributing to segment demand.

The market is divided into three categories based on End Users: hospitals, clinics, and others. The hospital segment dominates the market and is expected to maintain its high dominance during the forecast period. The advancement in technologies and treatment of skin, and kidney transmitted disorders are mainly boosting the market growth.

Sulphonamides Market- Geographical Insights

Worldwide, the Sulphonamides market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Developed regions with robust healthcare systems, such as North America, Western Europe, and parts of Asia-Pacific including Japan, Australia, etc. often have higher consumption of sulphonamides. This is due to better access to healthcare facilities. Countries in Latin America, Eastern Europe, Asia-Pacific (e.g., India, China), and Africa are experiencing increasing healthcare expenditure and improving healthcare infrastructure.

Sulphonamides Market- Competitive Landscape:

The Sulphonamides market is moderately competitive. Companies adapt their strategies to local market conditions, regulatory environments, and healthcare systems. Established players often have a global presence with distribution networks spanning multiple countries. Advances in manufacturing processes and technologies play a significant role in competitive positioning. Companies that adopt and integrate new technologies for production or formulation enhancement can improve efficiency and product quality. Further, competing companies invest heavily in R&D to develop new formulations, improve efficacy, and reduce the side effects of sulphonamide drugs. This ongoing research drives innovation and differentiation in the market.

Recent Developments:

In August 2022, Valeo Pharma Inc. formed a supply and commercialization agreement with Novartis Pharmaceuticals in Canada for the commercialization of SIMBRINZA.

In July 2022, Azurity Pharmaceuticals Inc. established endorsement from the US FDA for ZONISADE.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SULPHONAMIDES MARKET KEY PLAYERS

GLOBAL SULPHONAMIDES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019-2032

GLOBAL SULPHONAMIDES MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

GLOBAL SULPHONAMIDES MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

GLOBAL SULPHONAMIDES MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Sulphonamides Market Overview

2. Executive Summary

3. Sulphonamides Key Market Trends

4. Sulphonamides Industry Study

5. Sulphonamides Market: COVID-19 Impact Analysis

6. Sulphonamides Market Landscape

7. Sulphonamides Market - By Route of Administration

8. Sulphonamides Market - By Application

9. Sulphonamides Market - By End User

10. Sulphonamides Market- By Geography

11. Key Vendor Analysis- Sulphonamides Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â